ENERGI-F703
Phase 3Small molecule
ENERGI-F703 is one of 35 small molecule programs targeting Diabetic Foot. It is currently in Phase 3.
1
Indications
3
Total Trials
1
Active Trials
34
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
49 competitors in Diabetic Foot
#DrugCompanyPhaseTrials
1Desferal
Jazz PharmaceuticalsApproved
Remodulin
United TherapeuticsApproved
Vancocin
HHikma Pharmaceuticals LLC
Approved
Januvia
ZZydus Therapeutics Inc.
Approved
Sporanox
SSebela Pharmaceuticals Development LLC
Approved
Nitrostat
VViatris Specialty LLC
Approved
Inomax
MMallinckrodt
Approved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Tobrex
VViatris Specialty LLC
Approved
Esbriet
LLegacy Health System
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ENERGI-F703. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- EEnergenesis Biomedical Co., Ltd.